MetaVia is trading 9.09% lower at $1.30 after-hours; no specific reason for the pullback was supplied. - MetaVia closed at $1.43 on November 6, with the regular-session close up 31.19% following a volatile week. - On November 5, MetaVia announced interim Phase 1 data for DA-1726: a 68% placebo-adjusted reduction in liver fat and a 13.5% reduction in body weight after 16 weeks. - The small study included 19 participants; its results do not explain the after-hours decline.